Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTB41 and SCTB39-1 in Advanced Malignant Solid Tumours
NCT07594028Phase 2Not yet recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- May 2026
- Primary completion
- May 2029
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of SCTB41, SCTB39G in solid tumor, sponsored by Sinocelltech Group Limited. Planned start May 2026; status: not yet recruiting.
02
Drugs
SCTB41SCTB39G
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07594028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07594028.